Skip to content
Bored Studies
RecruitingPhase 3

[18F]PI-2620 Phase 3 Histopathological Study

Lantheus Biosciences Ltd. · NCT05641688

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 50+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
200
US sites recruiting
17
Study start
December 1, 2022
Record last updated
October 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Being studied: [18F]PI-2620

Conditions: Alzheimer Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Only subjects who meet all of the following criteria will be eligible for enrollment into the study:

  • Males and females aged 50 years and over
  • Have a projected life expectancy of ≤ 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (COPD), or end-stage cancer)
  • Written informed consent obtained from the subject and/or the subject's legally authorized representative (LAR), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the State in which the subject dies)
  • Can tolerate study procedures including lying down in PET scanner. The investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure

Exclusion Criteria

Subjects will be excluded from the enrollment if they:

  • Are receiving aggressive treatment with life sustaining measures (e.g. receiving chemotherapy; palliative chemotherapy is allowed)
  • Are known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment (e.g. lesions are typically > 2 cm at their greatest extent and may include stroke, primary or metastatic neoplasm, other tumors or cystic lesions. Subjects with a history of major stroke or traumatic brain injury or other structural lesion as well as cases with a history of primary Central Nervous System (CNS) neoplasm or known metastatic cancer must be discussed with the study sponsor prior to enrollment)
  • Have suspected encephalopathy due to alcoholism or end-stage liver disease
  • Are known to have a Glomerular Filtration Rate below \< 15 mL/min
  • Have received an investigational or approved therapy directly targeting amyloid or tau
  • Are females of childbearing potential who are pregnant, lactating or breastfeeding, or who are not using adequate contraception
  • Have implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI (in case an MRI is planned to be performed)

Recruiting US locations

Study contacts (from the official record)

  • Audrey Perrotin, PhD · +49 (0)30 461 1246 03 · clinicaltrials@lantheus.com
  • Aleksandar Jovalekic, PhD · +49 (0)30 461 1246 03 · clinicaltrials@lantheus.com
All neurology studies in Arizona →